Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm multicenter, phase II study. The primary objective is to
assess the efficacy of bemcentinib (BGB324) a highly selective inhibitor of the AXL receptor
tyrosine kinase for the treatment of AML and MDS patients failing or being refractory to
first line hypomethylating agent (HMA) treatment. Furthermore, safety, disease progression,
treatment failure will be assessed. A total of 43 patients will be included in the trial.
Phase:
Phase 2
Details
Lead Sponsor:
GWT-TUD GmbH
Collaborators:
BerGenBio ASA Groupe Francophone des Myelodysplasies VU University Medical Center